Orphazyme Financial Statements From 2010 to 2024
| ORPHA Stock | DKK 980.00 39.00 3.83% |
Check Orphazyme financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Orphazyme's main balance sheet or income statement drivers, such as , as well as many indicators such as . Orphazyme financial statements analysis is a perfect complement when working with Orphazyme Valuation or Volatility modules.
Orphazyme |
Orphazyme AS Company Return On Equity Analysis
Orphazyme's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Orphazyme Return On Equity | -4.87 |
Most of Orphazyme's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orphazyme AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Orphazyme AS has a Return On Equity of -4.8658. This is 79.7% lower than that of the Biotechnology sector and 86.65% lower than that of the Health Care industry. The return on equity for all Denmark stocks is notably higher than that of the company.
Orphazyme AS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Orphazyme's current stock value. Our valuation model uses many indicators to compare Orphazyme value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Orphazyme competition to find correlations between indicators driving Orphazyme's intrinsic value. More Info.Orphazyme AS is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Orphazyme by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Orphazyme's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Orphazyme Financial Statements
Orphazyme stakeholders use historical fundamental indicators, such as Orphazyme's revenue or net income, to determine how well the company is positioned to perform in the future. Although Orphazyme investors may analyze each financial statement separately, they are all interrelated. For example, changes in Orphazyme's assets and liabilities are reflected in the revenues and expenses on Orphazyme's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Orphazyme AS. Please read more on our technical analysis and fundamental analysis pages.
Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark.
Pair Trading with Orphazyme
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orphazyme position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orphazyme will appreciate offsetting losses from the drop in the long position's value.Moving against Orphazyme Stock
| 0.76 | DANSKE | Danske Bank AS | PairCorr |
| 0.43 | SYDB | Sydbank AS | PairCorr |
| 0.41 | GMAB | Genmab AS | PairCorr |
| 0.35 | NOVO-B | Novo Nordisk AS | PairCorr |
The ability to find closely correlated positions to Orphazyme could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orphazyme when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orphazyme - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orphazyme AS to buy it.
The correlation of Orphazyme is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orphazyme moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orphazyme AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orphazyme can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Orphazyme Stock
Orphazyme financial ratios help investors to determine whether Orphazyme Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Orphazyme with respect to the benefits of owning Orphazyme security.